Risk of Disease Progression Reduced by 80% in Phase 2 Gastric Cancer Trial

On June 5, Appclon announced that the first patient dosing (FPI) has been completed for the global Phase 3 clinical trial (HLX22-GC-301) of ‘HLX22 (AC101)’, a HER2-targeted gastric cancer treatment developed and licensed out by the company, in major countries including Korea.


A special interview video with Professor Lin Xuan from the Department of Oncology at Peking University Cancer Hospital, posted on the Henlius official channel on the 4th. Abclone

A special interview video with Professor Lin Xuan from the Department of Oncology at Peking University Cancer Hospital, posted on the Henlius official channel on the 4th. Abclone

View original image

Henlius, Appclon’s partner company, recently released an interview with Professor Lin Xuan of the Department of Oncology at Peking University Cancer Hospital. Professor Lin Xuan is recognized as an authority in the field of gastrointestinal cancers in Asia.


He explained that HLX22 is an antibody that binds to the same domain as the existing HER2-targeted therapy Herceptin (trastuzumab), but recognizes a different epitope. Combining the two antibodies can promote the internalization of the HER2 receptor into cells, thereby enhancing anticancer efficacy.


He particularly emphasized that HLX22 exhibits immunological properties that alter the tumor microenvironment (TME). He explained that when HLX22 is administered in combination therapy, tumor infiltration by CD8+ T cells, NK cells, and B lymphocytes increases, while M2 macrophages associated with immunosuppression decrease.


Professor Lin Xuan evaluated that these immune activation effects are also being reflected in clinical results. According to long-term follow-up data from a Phase 2 clinical trial with gastric cancer patients, progression-free survival (PFS) in the HLX22 combination group has not yet reached its median, and the risk of disease progression has been reduced by 80% compared to the control group. Overall survival (OS) has also not reached its median.


The global Phase 3 clinical trial of HLX22 is also progressing smoothly. According to the company, dosing of the first patient has been completed in all major regions—including Korea, China, Japan, the United States, Europe, Australia, and Central and South America—for the ongoing Phase 3 trial involving 550 patients with HER2-positive advanced gastric cancer.



An Appclon official stated, "HLX22 possesses a differentiated mechanism that not only blocks HER2 signaling but also improves the tumor microenvironment. We plan to accelerate commercialization by successfully completing the global Phase 3 clinical trial."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing